Though drug developers have achieved some progress in treating Alzheimer's disease with medicines that reduce amyloid-beta protein, other problems of the disease including inflammation, continue unchecked. In a new study, scientists at The Picower Institute for Learning and Memory at MIT describe a candidate drug that in human cell cultures and Alzheimer's mouse models reduced inflammation and improved memory.
that implicated PU.1 as a regulator of errant microglia inflammation in a mouse model of Alzheimer's disease. That research was a collaboration between Tsai's lab and that of MIT Computer Science Professor Manolis Kellis, co-led by former postdoc Andreas Pfenning, now a faculty member at Carnegie Mellon University. Ever since then, Tsai has been seeking a safe way to restore PU.1 activity to healthier levels.
They tested the effects of A11 doses on the function of human microglia-like cells cultured from patient stem cells. When they exposed the microglia-like cells to immune molecules that typically trigger inflammation, cells dosed with A11 exhibited reduced expression and secretion of inflammatory cytokines and less of the cell body shape changes associated with microglia inflammatory responses.
A11 treated Alzheimer's model mice showed much less tau than untreated controls . Credit: Tsai Lab/MIT Picower InstituteHaving established that A11 reduced inflammatory activity in microglia and determined how that happens, the team focused on whether it worked as a medicine in mouse models of Alzheimer's disease.
Male and female CK-p25 mice dosed with A11 showed less inflammatory response among microglia and astrocyte cells and lost fewer neurons than untreated controls. TauP301S Tg mice responded similarly, also exhibiting a significant reduction of phosphorylated tau protein in the hippocampus region of the brain, which is an essential area for memory. In 5XFAD mice, amyloid was significantly reduced.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Time-restricted feeding reverses Alzheimer's symptoms in mice, offers new hope for accessible treatmentResearchers explore the therapeutic potential of circadian-modulating interventions to treat Alzheimer’s disease.
Read more »
Scientists create 'hat' that detects Alzheimer's years before first symptomsIt has been hailed a 'fitness tracker for the brain'.
Read more »
Revolutionary new bedtime accessory detects Alzheimer's disease while you sleepIt has been hailed a 'fitness tracker for the brain'.
Read more »
Influenza and pneumonia vaccinations associated with reduced risk of Alzheimer’s diseaseFlu (influenza) and pneumonia vaccinations are associated with reduced risk of Alzheimer’s disease, according to new research reported at the Alzheimer’s Association International Conference (AAIC) 2020.
Read more »
How diet and exercise may rewrite the Alzheimer's script at a molecular levelResearchers explore how lifestyle changes like diet and physical activity can influence microRNA expression in Alzheimer's patients, potentially offering new therapeutic avenues. The study fills a research gap in understanding how such lifestyle modifications could affect molecular mechanisms implicated in Alzheimer’s disease.
Read more »
Online test nails early Alzheimer's diagnosis with biomarker precisionResearchers have developed a novel digital cognitive testing platform, using the Oxford Cognitive Testing Portal, that correlates with serological biomarkers to accurately measure cognitive impairment in Alzheimer's patients. The study highlights the platform's effectiveness in capturing subtle signs of impairment, potentially revolutionizing early diagnosis and tracking of Alzheimer's disease.
Read more »